Similar articles

• New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.

  Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. Rogatko A, et al. Clin Cancer Res. 2005 Aug 1;11(15):5342-6. doi: 10.1158/1078-0432.CCR-05-0458. Clin Cancer Res. 2005. PMID: 16061846
• Assessment of biological responses: what to measure and when.

  Maluish AE, Herberman RB. Maluish AE, et al. Cancer Treat Rep. 1985 Oct;69(10):1165-9. Cancer Treat Rep. 1985. PMID: 3899356
• Adaptive design may hasten clinical trials.

  Schmidt C. Schmidt C. J Natl Cancer Inst. 2007 Jan 17;99(2):108-9. doi: 10.1093/jnci/djk040. J Natl Cancer Inst. 2007. PMID: 17227993 No abstract available.
• Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

  El-Maraghi RH, Eisenhauer EA. El-Maraghi RH, et al. J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19. J Clin Oncol. 2008. PMID: 18285606 Review.
• Clinical trial designs for multiple myeloma.

  Hoering A, Crowley J. Hoering A, et al. Clin Adv Hematol Oncol. 2007 Apr;5(4):309-16. Clin Adv Hematol Oncol. 2007. PMID: 17607290 Review.